Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.01 better than the analyst estimate of ($1.73).

Cash, cash equivalents, and investments were $457.5 million as of June 30, 2017.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Carnival shares drop despite earnings beat on weak guidance
• BofA lists top 5 themes driving next $1tn in incremental semi sales